DENTSPLY SIRONA Inc. (XRAY) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $11.03. The rating moved from Neutral to Oversold on August 7, 2026.

• Public ratingOversold (as of August 19, 2026)
• Last close$11.03
• Last changeMoved from Neutral to Oversold on August 7, 2026
• SectorHealthcare
• IndustryMedical Instruments & Supplies

See all oversold Healthcare stocks →

AI analysis

DENTSPLY SIRONA Inc. (XRAY) benefits from a durable consumables business and a broad equipment/product portfolio that generates recurring revenue. Margin improvement initiatives and cost actions are beginning to show progress, but the company remains exposed to cyclical swings in dental procedure demand and execution risk on restructuring. Near-term upside is likely limited without clearer procedure-volume recovery or outsized earnings beats; monitor procedure trends, product adoption, and balance-sheet metrics for signs of directional change.

Key factors

• Large installed base and recurring consumables revenue provide steady cash flow and revenue visibility.
• Diverse product portfolio (imaging, CAD/CAM, equipment, consumables) supports cross-selling and aftermarket growth.
• Ongoing cost-reduction and restructuring efforts are improving margins but rely on execution.
• Exposure to dental procedure volumes ties near-term performance to discretionary healthcare demand and macro conditions.
• Competitive landscape includes regional low-cost manufacturers and technologically advanced competitors for premium equipment.
• Market environment is neutral to mildly defensive, limiting strong momentum catalysts in the immediate term.

Risks

• Decline or sluggish recovery in dental procedure volumes due to macro weakness or patient deferrals.
• Execution risk on turnaround plans, integration of product lines, and manufacturing/supply-chain bottlenecks.
• Elevated leverage or near-term refinancing needs that could pressure liquidity and limit strategic flexibility.
• Intense competition on pricing for equipment and consumables that could compress margins.
• Regulatory, product-quality, or recall events that could harm reputation and sales of key equipment lines.
• Foreign-exchange exposure and geographic revenue concentration risks in certain markets.

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.